<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45303">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02516527</url>
  </required_header>
  <id_info>
    <org_study_id>CA184-247</org_study_id>
    <nct_id>NCT02516527</nct_id>
  </id_info>
  <brief_title>A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether ipilimumab is effective in the treatment
      of select advanced (unresectable, metastatic, or recurrent) solid tumors in Chinese
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety of ipilimumab measured by the occurrence of adverse events, serious adverse events, adverse events leading to discontinuation and deaths</measure>
    <time_frame>Up to 90 days post discontinuation of dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The tolerability of ipilimumab measured by the occurrence of adverse events, serious adverse events, adverse events leading to discontinuation and deaths</measure>
    <time_frame>Up to 90 days post discontinuation of dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Identify dose limiting toxicities in Chinese subjects with select advanced (unresectable, metastatic, or recurrent) solid tumors measured by the occurrence of adverse events, serious adverse events, adverse events leading to discontinuation, and deaths</measure>
    <time_frame>Up to 90 days post discontinuation of dosing</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Induction Phase:Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ipilimumab dose as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance Phase:Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>umab dose as specified</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <arm_group_label>Induction Phase:Ipilimumab</arm_group_label>
    <arm_group_label>Maintenance Phase:Ipilimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com.

        Inclusion Criteria:

          -  Subjects with the following advanced solid tumors; metastatic or recurrent

          -  Must have measurable/non-measurable lesion per Response Evaluation Criteria in Solid
             Tumors (RECIST v1.1) criteria.

          -  Subjects have ability to comply with treatment, procedures and pharmacokinetics (PK)
             sample collection and the required study follow-up

          -  Chinese women and men, ages 18 years or older

        Exclusion Criteria:

          -  Subjects with brain metastases are excluded unless clinically stable for more than 4
             weeks at the time of randomization as determined by the investigator

          -  Subjects with ocular melanoma are excluded

          -  Any other malignancy from which the subject has been free of disease for less than
             two years, with the exception of adequately treated and cured basal or squamous cell
             skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix

          -  History of, or currently active, autoimmune diseases, including but not limited to
             inflammatory bowel disease, rheumatoid arthritis, autoimmune hepatitis, systemic
             sclerosis (scleroderma and variants), systemic lupus erythematosus, autoimmune
             vasculitis, autoimmune neuropathies (eg, Guillain-Barre syndrome). Vitiligo is not
             excluded

          -  Any current or history of immunodeficiency, splenectomy, or splenic radiation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 3, 2017</lastchanged_date>
  <firstreceived_date>July 3, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
